Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Silexion Therapeutics ( (SLXN) ) just unveiled an announcement.
On July 31, 2025, Silexion Therapeutics entered into an inducement offer letter agreement with holders of existing warrants to purchase 152,106 ordinary shares. The agreement involved reducing the exercise price of these warrants and issuing new warrants for additional shares, expecting to raise approximately $1.8 million. The company engaged H.C. Wainwright & Co. as the placement agent and agreed to various fees and issuance of additional warrants to the agent. The transactions are expected to close around August 1, 2025, with proceeds used for general corporate purposes.
The most recent analyst rating on (SLXN) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.
Spark’s Take on SLXN Stock
According to Spark, TipRanks’ AI Analyst, SLXN is a Underperform.
Silexion Therapeutics has significant financial difficulties with zero revenue and negative equity, posing major risks. Technical analysis indicates a bearish trend, and speculative valuation metrics reflect the high-risk nature of the stock. However, promising corporate developments, such as the SIL204 partnership and positive preclinical results, offer potential upside if clinical success is achieved.
To see Spark’s full report on SLXN stock, click here.
More about Silexion Therapeutics
Silexion Therapeutics Corp operates in the biotechnology industry, focusing on the development and commercialization of therapeutic products. The company primarily engages in offering ordinary shares and warrants as part of its financial strategies.
Average Trading Volume: 81,780
Technical Sentiment Signal: Sell
Current Market Cap: $8.66M
See more insights into SLXN stock on TipRanks’ Stock Analysis page.